Amyloid beta imaging with positron emission tomography (PET) to predict conversion to Alzheimer disease is considered investigational.
Amyloid beta imaging with PET as an adjunct to clinical diagnosis in individuals with dementia is considered investigational.
Amyloid beta imaging with PET to select individuals with mild cognitive impairment or mild dementia due to Alzheimer disease for amyloid beta targeting plaque-therapy is considered investigational.
Amyloid beta imaging with PET to evaluate individuals with mild cognitive impairment or mild dementia due to Alzheimer disease for continuation of amyloid beta plaque-targeting therapy is considered investigational.
PET Imaging with fluorine 18 fluorodeoxyglucose (FDG-PET) as an adjunct to clinical diagnosis in individuals with dementia is considered investigational.
All other uses of amyloid beta imaging with PET are considered investigational.
